All In Biotech

Drug Trial Radar · NCT07432022

A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EMB-07 (a Bispecific Antibody Targeting CD3 and Receptor-tyrosine-kinase-like Orphan Receptor 1 [ROR1]) Combination Therapy in Patients With Aggressive B-cell Non-Hodgkin Lymphoma

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

115

Planned (sponsor's estimate)

Start

Apr 1, 2026

Primary completion

Jun 30, 2028

Study completion Jun 30, 2028

Sponsor

Sponsor type
Industry
First posted
Feb 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of EMB-07 combination therapy in adult patients with aggressive B-cell non-Hodgkin lymphoma (B-NHL). The study consists two phases: Phase I of dose escalation and Phase II of dose expansion. Approximately 115 patients will be enrolled in this study (i.e., 5 cohorts of approximately 23 patients per cohort). Multiple EMB-07-based combination regimens will be evaluated in patients with relapsed/refractory (R/R) aggressive B-NHL (Cohort A) and patients with newly diagnosed aggressive B-NHL (Cohort B).

Conditions

  • Combination Therapy
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • EMB07
  • phaseI/II

Interventions

  • EMB07Drug

    EMB-07 is a bispecific antibody targeting CD3 and receptor-tyrosine-kinase-like orphan receptor 1 \[ROR1\]

  • Rituximab/Gemcitabine/OxaliplatinDrug

    Rituximab is a monoclonal antibody drug specifically targeting the CD20 antigen. Gemcitabine is a chemotherapy drug classified as an antimetabolite. Oxaliplatin is a platinum-based chemotherapy drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) of EMB-07(Phase I only)Time frame: Up to 28 days
  2. Rate of Adverse Events (AE) and Serious Adverse Events (SAE)Time frame: From enrollment up to 30 days after the last dose
  3. Recommended phase II dose (RP2D) of EMB-07Time frame: Up to 28 days
  4. Objective Response Rate (ORR)Time frame: From first dose until the date of first documented progression or date of death from any cause, whichever comes first, up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aerospace Central Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.